Randomized, open-label, prospective study to evaluate the safety and efficacy of sofosbuvir plus daclatasvir or ravidasvir in Egyptian adults with COVID-19
Latest Information Update: 12 Nov 2021
At a glance
- Drugs Daclatasvir (Primary) ; Ravidasvir (Primary) ; Sofosbuvir (Primary) ; Antibacterials; Anticoagulants; Heparin; Hydroxychloroquine; Ivermectin; Lopinavir/ritonavir; Multivitamin; Paracetamol; Remdesivir; Steroids; Tocilizumab
- Indications COVID-19 respiratory infection
- Focus Registrational; Therapeutic Use
- Acronyms SAVE
- Sponsors European Egyptian Pharmaceutical Industries
- 01 Dec 2021 Results published in the Journal of Medical Virology
- 30 Mar 2021 New trial record